Reports Q4 revenue $45.78M, consensus $48.46M. “2023 was a year of execution for MRD and strategic evolution for IM. The MRD business ended the year with 53% growth in clonoSEQ tests delivered and IM achieved key target and drug discovery milestones in cancer and autoimmune disorders,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “2024 is off to a strong start. As momentum continues to build in both MRD and IM, we look forward to maximizing the value of each of these distinct opportunities for our patients and shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADPT:
- Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
- Adaptive Biotechnologies (ADPT) Q4 Earnings Cheat Sheet
- Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
- Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
